Dimopoulos, M., Wang, M., Maisnar, V., Minarik, J., Bensinger, W., Mateos, M., . . . Moreau, P. (2018). Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol Oncol.

Dimopoulos, Meletios, Michael Wang, Vladimir Maisnar, Jiri Minarik, William Bensinger, Maria-Victoria Mateos, Mihaela Obreja, Julie Blaedel, i Philippe Moreau. "Response and Progression-free Survival According to Planned Treatment Duration in Patients With Relapsed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd) in the Phase III ASPIRE Study." J Hematol Oncol 2018.

Dimopoulos, Meletios, et al. "Response and Progression-free Survival According to Planned Treatment Duration in Patients With Relapsed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd) in the Phase III ASPIRE Study." J Hematol Oncol 2018.